SB-284851-BT
SB-284851-BT is an inhibitor of BRD4/p38α/BRDT. SB-284851-BT inhibits BRD4-BD1 (IC50=1.7 µM), p38α (Kd=0.47 nM), BRDT (1) (IC50=18 µM) and BRD4 (1)(IC50=3.7 µM). SB-284851-BT reduces IL-8 production by inhibiting p38α, as well as inhibiting BRD4 to down-regulates c-Myc and NF-κB gene pathways in cancer. SB-284851-BT can combined with the bromine domain and extra terminal (BET).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 219769-23-0
- Formel: C26H26FN5O
- Molecular Weight:443.52
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
p38α 0.47 nM (Kd) |
BRD4-BD1 1.7 μM (IC50) |
BRDT (1) 18 μM (IC50) |
BRD4(1) 3.7 μM (IC50) |
Chemical Information
-
CAS. Nr. 219769-23-0
-
Molecular Weight 443.52
-
Formel C26H26FN5O
-
SMILES
FC1=CC=C(C2=C(C3=NC(OC4=CC(C)=CC(C)=C4)=NC=C3)N(C5CCNCC5)C=N2)C=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Divakaran A, et al. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem. 2018 Oct 25;61(20):9316-9334. [Content Brief]
[2]. Jin W, et al. Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions. Drug Discov Today. 2022 Jan;27(1):246-256. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
SB-284851-BT Related Classifications
HY-136794 Related Classifications
Powered by Bioz